Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company Kannalife, Inc. (“Kannalife”) (OTCQB: KLFE) has appointed biotech
|
SAN DIEGO, June 4, 2020 /PRNewswire/ -- Medical Marijuana, Inc. Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company Kannalife, Inc. ("Kannalife") (OTCQB: KLFE) has appointed biotechnology and pharmaceutical industry veteran Terrence O. Tormey to the company's Board of Advisors. "Kannalife continues to prove itself as a leader in cannabinoid research and its reputation to add well-respected biotech and pharmaceutical leaders like Terrence Tormey to its team amplifies its efforts," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "It's an honor to have Terry join our advisory board because his experience, vision and knowledge in the life sciences industry will help us start to design our commercialization and distribution plan for Atopidine™," said Dean Petkanas, CEO of Kannalife. Mr. Tormey brings over four decades of experience in the life sciences industry and has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson). Most recently he was the CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. "I am honored to serve as an advisor to Kannalife. The company has remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN) that, when approved, will help improve the lives of hundreds of thousands of patients," Tormey said. About Medical Marijuana, Inc. Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop. About Kannalife, Inc. Atopidine™ is Kannalife's novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6. KLS-13019 is Kannalife's leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research. The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA. For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company's Twitter page at @Kannalife. FORWARD-LOOKING DISCLAIMER FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE LEGAL DISCLOSURE CONTACT: Investor Relations Contact:
SOURCE Medical Marijuana, Inc. |
||
Company Codes: OTC-PINK:MJNA, OTC-PINK:KLFE, OTC-QB:KLFE |
View original content:
